Final NICE no for BMS’ Opdivo in urothelial carcinoma
admin 4th July 2018 Uncategorised 0The National Institute for Health and Care Excellence has now issued final guidance rejecting NHS funding for use of Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).
More: Final NICE no for BMS’ Opdivo in urothelial carcinoma
Source: News